At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 70 enrolled
Drug / intervention
Zoledronic acid +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss
In Brief
A Phase 3 clinical trial evaluating Zoledronic acid and Placebo for Breast Cancer. Completed, enrolled 70 participants across 1 site.
Detailed Summary
This study examines the safety and efficacy of zoledronic acid 4 mg., given every 3 months over 24 months (infusion at month 0, 3, 6, 9, 12, 15, 18 and 21) in improving bone mineral density in premenopausal women with hormone receptor negative breast cancer and adjuvant chemotherapeutic treatment
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesGermany
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2005
First PostedSep 2006
Primary CompletionMay 2014
TodayJul 2026
First PostedSep 13, 2006
Enrollment StartOct 1, 2005
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 8.6 yearsPosted 19.8 years ago
Interventions
Zoledronic aciddrug
Placebodrug
Placebo